Overview

* QuidelOrtho ( QDEL ) reports Q3 revenue of $700 mln, beating analysts' expectations

* Adjusted EPS beats consensus, reflecting effective cost-savings initiatives

* Company reports goodwill impairment charge of $701 mln, impacting GAAP net loss

Outlook

* QuidelOrtho ( QDEL ) sees full-year 2025 revenue between $2.68 bln and $2.74 bln

* Company expects full-year 2025 adjusted EBITDA of $585 mln to $605 mln

* QuidelOrtho ( QDEL ) forecasts full-year 2025 adjusted EPS between $2.00 and $2.15

Result Drivers

* REVENUE DECLINE - Total revenue decreased 4% due to lower COVID-19 and Donor Screening revenue

* COST-SAVINGS INITIATIVES - Decreased operating expenses and improved adjusted EBITDA margin attributed to cost-savings measures

* DEBT REFINANCING - Successful debt refinancing improved financial flexibility through better terms and reduced obligations

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $699.9 $664.96

Revenue mln mln (8

Analysts

)

Q3 Beat $0.80 $0.46 (7

Adjusted Analysts

EPS )

Q3 EPS -$10.78

Q3 Net -$733

Income mln

Q3 Basic -$10.78

EPS

Q3 -$704.8

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

* Wall Street's median 12-month price target for QuidelOrtho Corp ( QDEL ) is $34.00, about 20.2% above its November 4 closing price of $27.13

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)